Efficacy of High Dose Radiotherapy in Post-operative Treatment of Glioblastoma Multiform - A Single Institution Report

  • Pashaki, Abdolazim Sedighi ;
  • Hamed, Ehsan Akbari ;
  • Mohamadian, Kamal ;
  • Abassi, Mohammad ;
  • Safaei, Afsane Maddah ;
  • Torkaman, Tayebe
  • Published : 2014.03.30


Background: Glioblastoma multiform (GBM) is a highly aggressive tumor with median survival of approximately 14 months. Management consists of maximal surgical resection followed by post-operative chemoradiation with concurrent then adjuvant temozolamide. The standard radiotherapy dose is 60Gy in 2-Gy fractions recommended by the radiation therapy oncology group (RTOG). With the vast majority of tumor recurrences occurring within the previous irradiation field and the poor outcome associated with standard therapy, regimens designed to deliver higher radiation doses to improve local control and enhance survival are needed. In this study, we report a single institutional experience in treatment of 68 consecutive patients with GBM, treated with resection, and given post-operative radiotherapy followed by concurrent and/or adjuvant chemotherapy. Results: Of the 80 patients who entered this study, 68 completed the treatment course; 45 (66.2%) males and 23 (33.8%) females with a mean age at diagnosis of $49.0{\pm}12.9$ (21-75) years. At a median follow up of 19 months, 39 (57.3%) patients had evidence of tumor progression and 36 (52.9%) had died. The median over all survival for all patients was 16 months and progression free survival for all patients was 6.02 months. All potential prognostic factors were analyzed to evaluate their effects on overall survival. Age ${\leq}50$ year, concurrent and adjuvant chemotherapy and extent of surgery had significant p values. We found lower progression rate among patients who received higher doses of radiotherapy (>60Gy). Higher radiation doses improved progression free survival (p=0.03). Despite increasing overall survival, this elevation was not significant. Conclusions: This study emphasize that higher radiation doses of (>60Gy) can improve local control and potentially survival, so we strongly advise prospective multi centric studies to evaluate the role of higher doses of radiotherapy on GBM patient outcome.


GBM surgery;high dose radiotherapy;chemotherapy;outcome


  1. Stupp R, Mason WP, Vonder ben t MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastom. New Eng J Med, 352, 987-96.
  2. Tanaka M, Ino Y, Nakagava K, et al (2005). High dose conformal radiotherapy for supra tentorial malignant glioma: a historical comparison. Lancet Oncol, 6, 953-60.
  3. Julka PK, Sharma DN, Mallicks (2013). Post operative treatment of glioblastoma multiform: a mono institutional experience of 215 Patients. J Cancer Res Ther, 9, 381-6.
  4. Jalali R, Basa A, Gupta T, et al (2007). Encouraging experience of concomitant temozalamide with radiotherapy in newly diagnosed glioblastoma multiform: single institutional experience. Br J Neurosurg, 21, 583-7.
  5. Jazayeri B, Movaghar V, shokran F, et al (2013). Epidemiology of primary CNS tumor in Iran: a systemic review. Asian Pac J Cancer Prev, 14, 3979-86.
  6. Jeon HJ, Kong DS, park KB, et al (2009). Clinical out come of concomitant chemoradiotherapy followed by adjuvant temozolamid therapy for glioblastomas: single center experience. Clin Neural Neurosurg, 111, 679-82.
  7. Kleihues P, Cavanee WK, eds (2000). World Health Organization classification of tumors: pathology and genetics of tumors of the nervous system, Lyon, France: IARC press.
  8. Mac Donald On, Cascino TL, Schold SC, et al (1990). Response criteria for phase II studies of supra tentorial malignant glioma. J Clin Oncol, 8, 1277-80.
  9. Mirimanoff Ro, Gorlia T, Mason W, et al (2006). Radiotherapy and temozolamide for newly diagnosed glioblastoma: recursive partitioning Analysis of the EORTC 26981. J Clin Oncol, 24, 2563-9.
  10. Nelson DF, Diener WM, Horton J, et al (1988). Combined modality approach to malignant gliomas-reevaluation of RTOG7401/ECOG 1374 with long term follow up, NCI Monogr, 6, 279-84.
  11. Roldan GB, Scot JN, Hamilton MG, et al (2009). Population based study of pseudo progression after chemo radiotherapy in GBM, Can J Neuro Sci, 36, 617-22.
  12. Sanghera P, Perry J, Davey P, et al (2010). Pseudoprogression following chemoradiotherapy for glioblastoma multiform. Can J Neural Sci, 37, 36-42.
  13. Adamson C, Kanu O, Mehta A, et al (2009). Glioblastoma multiform: a review of where we have been and where we are going. Expert Opin Investing Drugs, 18, 1061-83.
  14. Ahmadloo N, Kani A, Mohamadian Panah M (2013). Treatment out come and prognostic factors of adult glioblastoma multiform. J Egypt Natl Canc Inst, 25, 21-30.
  15. Chose A, lim G, Husain S (2010). Treatment for glioblastoma multiform: Current guidelines and Canadian practice. Current Oncol, 17, 52-60.
  16. Colman H, Berkey BA, Maor MH, et al (2006). Phase II radiation therapy oncology group trial of conventional radiation followed by treatment with recombinant interferon for glioblastoma result of RTOG 9710. Int J Radiat Oncol Biol Phys, 66, 818-24.
  17. Curran WJ, Scott CB, Horton J, et al (1993). Recursive petitioning analysis of prognostic factors in three Radiation therapy oncology group malignant glioma trials. J Nat Cancer Inst, 85, 701-10.
  18. Gladwish A, Koh ES, Hoisak J, et al (2011). Evaluation of early imaging response criteria in glioblastoma multiform. Radiat Oncol, 6, 121.
  19. Ho J, Ondo SJ, Ning H (2013). Chemoradiation for glioblastoma multiform: the National cancer institute experience, Plos ONE, 8, 70745.

Cited by

  1. Clinicopathological Findings and Five Year Survival Rates for Patients with Central Nervous System Tumors in Yazd, Iran vol.15, pp.23, 2015,
  2. Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation vol.15, pp.24, 2015,
  3. Clinical Observation of Three Dimensional Conformal Radiotherapy with Tamoxifen in Treatment of Postoperative Malignant Glioma vol.16, pp.5, 2015,
  4. Genomic and Molecular Characterization of Brain Tumors in Asian and Non-Asian Patients of Los Angeles: A Single Institution Analysis vol.5, pp.2, 2017,